August 1946 in “Journal of the American Medical Association” Companies agreed to stop false advertising about their products' health benefits.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for hair loss and prostate issues without hormonal side effects.
8 citations
,
June 2024 in “Pharmaceutics” PEA-ENL improves skin delivery and reduces inflammation without side effects.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
April 1989 in “Archives of Dermatology” Pharmaceutical ads for Rogaine and Accutane may be misleading and not financially sensible.
DiluCap improves how quickly minoxidil and finasteride dissolve and controls the release of melatonin and naltrexone.
April 2026 in “ACS Applied Materials & Interfaces” A new treatment using probiotic microneedles shows promise for promoting hair growth and reducing inflammation in androgenetic alopecia.
October 2023 in “Applied materials today” New treatment for hair loss using special microneedles shows promise in reducing inflammation and promoting hair growth.
September 2020 in “Eureka: Health Sciences” The emulgel with specific ingredients was effective for treating hair loss.
October 2025 in “Pharmaceuticals” Auranofin shows promise as a cancer treatment, especially when combined with other therapies.
2 citations
,
December 2022 in “PNAS nexus” SCD-153 shows promise as an effective topical treatment for alopecia areata.
November 2025 in “Journal of Investigative Dermatology” AMP-303 injections can increase hair growth in androgenetic alopecia with minimal side effects.
June 2023 in “Skin Research and Technology” The supplement with amino acids, iron, selenium, and marine hydrolyzed collagen improved hair growth more than drug treatment alone, with most people tolerating it well.
November 2025 in “Clinical and Translational Allergy” The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in personalized therapy, health literacy, and patient care across various health conditions.
January 2017 in “The American Pharmacists Association eBooks” January 2017 in “The American Pharmacists Association eBooks”
2 citations
,
May 2021 in “Clinical Pharmacology in Drug Development” Clascoterone is safe for the heart, even at high doses.
18 citations
,
February 2025 in “Drug Delivery and Translational Research” The microneedle patches effectively treat allergic conjunctivitis with controlled, sustained release of medication.
July 2024 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.
February 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.
January 2026 in “Zenodo (CERN European Organization for Nuclear Research)” LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
15 citations
,
July 2009 in “Biomedical Chromatography” A reliable method was developed to measure aristolochic acid-I in rat blood.
27 citations
,
December 2015 in “Clinical and Experimental Dermatology” Diphencyprone helped most patients with alopecia areata regrow some hair.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
25 citations
,
December 2001 in “Expert Opinion on Pharmacotherapy” Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.